Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 28, 2014 (13 years ago)

Metformin HCl Extended-Release Tablets (Metformin Hydrochloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Tablet; customer complaint of some tablets of Gabapentin found in a bottle of Metformin HCl ER

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Metformin HCl Extended-Release Tablets, USP, 500 mg, Rx only, 500 count bottles, Manufactured by: Sun Pharmaceutical Inc. Ltd, Andheri (East) Mumbai-400 059, India, Distributed by: Caraco Pharmaceutical Laboratories, Ltd, Detroit, MI --- NDC 62756-142-02

Affected NDC 62756-0142-02

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Metformin Hydrochloride
NDC 62756-0142
500 mg/1 Tablet, Extended Release
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Caraco Pharmaceutical Laboratories, Ltd.
NDC code
62756-142-02
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1089-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Caraco Pharmaceutical Laboratories, Ltd.

All 2014 recalls
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-294-88 D-1511-2014
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-293-88 D-1510-2014
Class II · Moderate risk

Gemcitabine For Injection USP

Lack of Assurance of Sterility: A particle excursion for a different batch of the same product may lead to a lack of sterility assurance.

Terminated Sterility / contamination Caraco Pharmaceutical Laboratories, Ltd. NDC 47335-154-40 D-1407-2014